Clinical trials: Schizophrenic Disorders
Schizophrenia, Diabetes Mellitus, Type 2
Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia
The purpose of this study is to determine the efficacy of combining open-label extended release bupropion (flexible dosing up to 450mg target) and naltrexone (37.5mg) versus Bupropion and placebo along with a daily 500 calorie…
- Conditions
- Schizophrenia, Diabetes Mellitus, Type 2, Obesity
- Trial name
- NBC (NCT03132571)
- Testing
- Naltrexone, Bupropion
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Yale University
Alcohol Abuse, Schizophrenia
Contingency Management of Alcohol Abuse in the Severely Mentally ILL
The investigators will evaluate the efficacy of a comprehensive 12-week contingency management intervention for treating alcohol dependence for persons with severe mental illness who are seen within the context of a community…
- Conditions
- Alcohol Abuse, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- CMETG (NCT01567943)
- Testing
- Contingency Management
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- University of Washington
Schizophrenia, Schizoaffective Disorder
Glucose and Lipid Metabolism on Antipsychotic Medication
This project aims to a) evaluate the effects of selected antipsychotic medications on insulin action in skeletal muscle (glucose disposal), liver (glucose production) and adipose tissue (whole-body lipolysis), b) evaluate the…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Type 2 Diabetes Mellitus, Hyperglycemia
- Trial name
- Glulipid (NCT00515723)
- Testing
- risperidone, olanzapine, quetiapine
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- Washington University School of Medicine
Schizophrenia
Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia
This study is to assess the pharmacodynamics, pharmacokinetics, safety and tolerability of multiple ascending doses of AZD0328 in patients with schizophrenia
- Trial name
- NCT00669903
- Testing
- AZD0328
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Schizophrenia
Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects
To evaluate the pharmacokinetic (PK) characteristics after multiple oral administration of 40 mg lurasidone in healthy Chinese subjects.
- Trial name
- NCT02174523
- Testing
- 40mg lurasidone
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Alcohol Dependence, Schizophrenia
Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism
The aim of this study is to evaluate the safety and efficacy of acamprosate for patients with alcohol dependence and comorbid schizophrenia spectrum disorders.
- Trial name
- NCT00463346
- Testing
- Acamprosate
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Yale University
Acute Schizophrenia
Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia
The purpose of this study is to assess the efficacy, safety, and tolerability of fixed doses of OPC-34712 versus placebo for the treatment of adult subjects with an acute relapse of schizophrenia.
- Trial name
- BEACON (NCT01393613)
- Testing
- OPC-34712
- Where
- 60 sites in United States, Colombia and 6 more
- Volunteers
- 674 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Healthy, Schizophrenia
Modulating Human Cortical Plasticity With Transcranial Electrical Stimulation
Experience dependent plasticity is a fundamental property of the brain. It allows neural systems to adapt in response to environmental input and subserves the vital functions of learning and memory.
- Trial name
- NCT03114488
- Testing
- tDCS
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Schizophrenia
Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia
To provide treatment to eligible subjects who have successfully completed one of the following phase III ziprasidone studies, A1281028, A1281044, A1281045 (NCT00136994) or A1281088 (NCT00143351).
- Trial name
- NCT00139737
- Testing
- Ziprasidone
- Where
- 87 sites in Italy
- Volunteers
- 344 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Schizoaffective Disorder
Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain
The study attempts to evaluate a histamine analog long used for the treatment of Meniere's disease, betahistine, that shows promise in reversing the antihistaminergic effects thought to be involved in antipsychotic induced weight…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar I Disorder
- Trial name
- NCT00709202
- Testing
- Betahistine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia
Safety and Efficacy of Cariprazine in Patients With Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.
- Trial name
- NCT01104766
- Testing
- Cariprazine, Aripiprazole
- Where
- 58 sites in United States, Romania and 2 more
- Volunteers
- 617 people
- Sponsor
- Forest Laboratories
Schizophrenia, Schizoaffective Disorder
The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.
The purpose of this study is to learn how to help veterans play a stronger role in shaping their mental health care. Specifically we want to see if we can help veterans improve their mental health treatment by helping them decide…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depression
- Trial name
- NCT00466323
- Testing
- Family Member Provider Outreach, Enhanced treatment as usual (e-TAU)
- Where
- 2 sites in United States
- Volunteers
- 238 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia, Schizo-affective Disorder
Effects of Metformin and Fish Oil on Treatment With Clozapine
One purpose of this study is to test whether adding metformin will limit some of the unwanted effects of clozapine, compared to not adding metformin.
- Trial name
- NCT02140788
- Testing
- Metformin, Fish Oil
- Volunteers
- 34 people
- Sponsor
- Duke University
Cannabis Dependence, Marijuana Dependence
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
Cannabis use disorders are an important public health problem in the United States, but no effective pharmacotherapies are available to treat these disorders.
- Trial name
- DCCS (NCT01598896)
- Testing
- Dronabinol, Clonidine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mclean Hospital
Schizophrenia Schizoaffective, Schizophrenia
TMS Related Biomarker Assessments
Patients with schizophrenia spectrum disorder (SSD) will be exposed to active and sham repetitive transcranial magnetic stimulation (rTMS) in separate sessions.
- Trial name
- NCT05660018
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Maryland, Baltimore
Cannabis-Related Disorder, Substance-Related Disorders
First Episode Schizophrenia and Cannabis-Related Disorder Study
Many individuals with schizophrenia abuse cannabis at the onset of their illness, portending a poorer course of illness and poorer treatment response.
- Conditions
- Cannabis-Related Disorder, Substance-Related Disorders, Schizophrenia, Psychotic Disorders
- Trial name
- NCT00573287
- Testing
- clozapine, risperidone
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia
Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone
The purpose of this study is to evaluate medication satisfaction after at least 4 weeks of paliperidone ER (extended-release), an antipsychotic, treatment in patients with schizophrenia who were previously taking either 4 or 6 mg…
- Trial name
- NCT00535132
- Testing
- Oral Risperidone, Paliperidone ER
- Where
- 40 sites in United States, Argentina and 4 more
- Volunteers
- 201 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
A Definitive Estrogen Patch Study (ADEPT)
OBJECTIVE: To test the use of adjunctive estrogen in a 8 week, three-arm, double-blind, placebo-controlled study in the treatment of psychotic symptoms in women with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder(Not in Manic Phase)
- Trial name
- NCT00357006
- Testing
- Estradiol
- Where
- Australia
- Volunteers
- 180 people
- Sponsor
- The Alfred
Schizophrenia
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
Evaluate the clinical outcome of two switching strategies to iloperidone treatment in adult subjects with schizophrenia who require a change in their current antipsychotic treatment of risperidone, olanzapine, or aripiprazole due…
- Trial name
- i-FANS (NCT01207414)
- Testing
- iloperidone
- Where
- 59 sites in United States
- Volunteers
- 501 people
- Sponsor
- Novartis
Schizophrenia
A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
The study will evaluate the antipsychotic efficacy of ITI-007 in a randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation…
- Trial name
- NCT02469155
- Testing
- ITI-007, Risperidone
- Where
- 11 sites in United States
- Volunteers
- 696 people
- Sponsor
- Intra-Cellular Therapies, Inc.